Acalabrutinib (Calquence) - Oncology Nurse Advisor
Skip to navigation Skip to main content

Acalabrutinib (Calquence)

Slideshow

  • Acalabrutinib_Slide01

  • Acalabrutinib_Slide02

  • Acalabrutinib_Slide03

  • Acalabrutinib_Slide04

  • Acalabrutinib_Slide05

  • Acalabrutinib_Slide06

  • Acalabrutinib_Slide07

  • Acalabrutinib_Slide08

  • Acalabrutinib_Slide09

  • Acalabrutinib_Slide10

  • Acalabrutinib_Slide11

  • Acalabrutinib_Slide12

  • Acalabrutinib_Slide13

  • Acalabrutinib_Slide14

  • Acalabrutinib_Slide15

  • Acalabrutinib_Slide16

  • Acalabrutinib_Slide17

  • Acalabrutinib_Slide18

  • Acalabrutinib_Slide19

  • Acalabrutinib_Slide20

  • Acalabrutinib_Slide21

  • Acalabrutinib_Slide22

  • Acalabrutinib_Slide23

 

This slideshow reviews acalabrutinib (Calquence), indicated for the treatment of myelodysplastic syndrome (MDS).

Table of Contents

Slide 4: Dosage and Administration
Slide 11: Cautions, Effects, and Interactions
Slide 17: What to Tell Your Patient
Slide 23: Reference

 

Topics:

Drug Information Slideshows Stat Consult
Next hm-slideshow in Slides